Early-Stage trial halted after testing drug duo for tough prostate cancer
NCT ID NCT05037500
Summary
This early-stage trial aimed to see if adding a new oral drug (decitabine/cedazuridine) to a standard prostate cancer drug (enzalutamide) was safe and could help overcome treatment resistance. It involved 8 men with advanced prostate cancer that had spread and stopped responding to standard hormone therapy. The main goal was to find a safe dose and check for side effects, but the study was terminated early.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IVB PROSTATE CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
Conditions
Explore the condition pages connected to this study.